Five participants discontinued hypnotics in a small feasibility series. Masking the schedule occurred with consent and alongside behavioral treatment, not as an isolated or covert intervention.
Participants agreed to taper without knowing the exact schedule or capsule contents at each step. Cognitive behavioral therapy for insomnia accompanied the medication changes. All five discontinued their hypnotic after treatment and reported improvements in selected sleep-related measures.
The series explored feasibility and patient experience rather than assigning people to masked versus open tapering.
Motivation, behavioral treatment, clinical support, expectancy, and medication changes could all contribute. Five selected cases cannot establish a general success rate or uncommon withdrawal-event safety.
The report cannot justify secretly changing a patient’s medicines or assuming the schedule fits every benzodiazepine exposure. Its useful distinction is between a consented research strategy and demonstrated comparative benefit. Individual taper decisions still require the actual exposure history and clinical response.
Original analysis of the supplied journal article, identified as PMC6822133.